ロード中...
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Despite advances in the treatment of multiple myeloma, it remains an incurable disease, with relapses and resistances frequently observed. Recently, immunotherapies, in particular, monoclonal antibodies, have become important treatment options in anticancer therapies. Elotuzumab is a humanized monoc...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5063562/ https://ncbi.nlm.nih.gov/pubmed/27785050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S94531 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|